~~<i id='447D5D47CC'><strike id='447D5D47CC'><tt id='447D5D47CC'><pre id='447D5D47CC'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：explore 2025-09-28 00:10:38 Page View：74886

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Living organ donors deserve priority status for transplants
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

explore

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

FILE-PrinceHarryleavestheHighCourtaftergivingevidenceinLondon,Wednesday,June7,2023.PrinceHarryisseek

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

1:29PoliceandanimalcontrolofficersinEdwardsville,Kansas,workedtogetherwiththeBonnerSpringsPoliceDepa